Waters Financial Model

• Total assets: Approximately $3.5 billion prior to the BD transaction.
• Key asset categories: Cash, accounts receivable, inventory, and a growing base of acquired intangibles.
• Goodwill & intangibles as % of total assets: Approximately 45% to 50%, driven largely by the 2023 Wyatt Technology acquisition.
• Working capital profile:
• Days Sales Outstanding (DSO): 60 to 70 days.
• Days Inventory Outstanding (DIO): 90 to 100 days.
• Days Payable Outstanding (DPO): 30 to 40 days.
• Net working capital as % of revenue: Typically positive 15% to 20%.
• Is working capital positive or negative?: Positive. The company requires working capital to fund inventory for its global supply chain.
• PP&E: Manufacturing facilities (including column manufacturing in Taunton, Massachusetts), demonstration equipment, and tooling.
• Right-of-use assets / operating leases: Material but manageable, representing global sales and service offices.

• Capex as % of revenue: 3.0% to 4.0%.
• Maintenance capex vs. growth capex: Approximately 60% maintenance and 40% growth (facility expansions).
• Major capex programmes underway or planned: Expansion of precision chemistry manufacturing capacity.
• Capitalised software / development costs if material: Minimal relative to total capex; most R&D is expensed as incurred.
• M&A pattern: Transitioned from organic growth with small bolt-ons to transformational M&A (Wyatt Technology and the pending BD transaction).
• Typical acquisition multiple paid: High teens to low twenties EBITDA multiples for high-growth life science assets.

• Total debt: Approximately $1.5 billion pre-merger.
• Debt/EBITDA ratio: Historically below 1.5x, but expected to rise to approximately 2.3x upon closing the BD transaction.
• Credit rating: Investment grade.
• Key debt instruments: Senior unsecured notes and a revolving credit facility.
• Maturity profile: Staggered maturities over the next 5 to 10 years.
• Interest rate profile: Predominantly fixed rate via senior notes.
• Covenants: Standard leverage and interest coverage ratios.
• Share repurchase programme: Historically active, but capital allocation will pivot towards debt paydown following the BD transaction.
• Dividend policy: The company does not currently pay a regular dividend.

• Operating cash flow conversion: Consistently strong, typically 1.1x to 1.2x of Net Income.
• Free cash flow margin: Approximately 25% of revenue.
• Major non-cash items that bridge net income to OCF: Depreciation, amortisation of acquired intangibles, and stock-based compensation.
• Working capital cash flow impact: Modest use of cash as the business grows.
• Capex intensity: Low, allowing for massive free cash flow generation.
• Cash tax rate vs. GAAP effective tax rate: Cash taxes are generally aligned with the GAAP effective tax rate of approximately 15.0%.

1. Assumptions: Hardcoded drivers for macro variables, segment growth, margins, tax rates, and specific inputs for the BD transaction.
2. Revenue Build: Detailed buildup of revenue by product type (Instruments, Chemistry, Service) and cross-checked by operating segment (Waters, TA).
3. Income Statement: GAAP and Non-GAAP views, clearly separating amortisation of acquired intangibles and restructuring costs.
4. Working Capital: Schedules for accounts receivable, inventory, accounts payable, and deferred revenue based on days outstanding metrics.
5. PP&E & Intangibles: Capex, depreciation waterfall, and amortisation schedules for Wyatt and BD intangibles.
6. Debt Schedule: Pre-merger debt tranches, the new $4.0 billion SpinCo debt assumption, interest expense calculations, and mandatory paydowns.
7. M&A Pro-Forma: A dedicated sheet modelling the Reverse Morris Trust transaction, including the 60.7 million share issuance, debt assumption, and consolidated financials.
8. Cash Flow Statement: Indirect method reconciling net income to ending cash.
9. Balance Sheet: Standard format balancing via the revolving credit facility or excess cash.
10. Valuation: Unlevered free cash flow build, WACC calculation, and DCF output.

1. "Total Revenue = Instruments Revenue + Chemistry Revenue + Service Revenue"
2. "Instruments Revenue = Prior Year Instruments Revenue x (1 + Instrument Growth Rate)"
3. "Chemistry Revenue = Prior Year Chemistry Revenue x (1 + Chemistry Growth Rate)"
4. "Service Revenue = Prior Year Service Revenue x (1 + Service Growth Rate)"
5. "Gross Profit = Total Revenue - (Instruments COGS + Chemistry COGS + Service COGS)"
6. "Adjusted Operating Income = Gross Profit - R&D Expense - SG&A Expense"
7. "GAAP Operating Income = Adjusted Operating Income - Amortisation of Acquired Intangibles - Restructuring Charges"
8. "Pro-Forma Share Count = Current Shares Outstanding + 60.7 million"
9. "Pro-Forma Debt = Current Debt + 4000 million"
10. "Interest Expense = (Average Pre-Merger Debt x Pre-Merger Rate) + (Average SpinCo Debt x SpinCo Rate)"
11. "Deferred Revenue Ending Balance = Deferred Revenue Beginning Balance + New Service Billings - Recognised Service Revenue"
12. "Free Cash Flow = Operating Cash Flow - Capital Expenditures"

The Assumptions sheet dictates the growth rates and margin profiles on the Revenue Build and Income Statement sheets. The M&A Pro-Forma sheet is critical; it feeds the Revenue Build (adding BD segment revenue), the Debt Schedule (adding $4.0 billion in assumed debt), and the Valuation sheet (adjusting the share count). The Income Statement generates net income, which flows to the Cash Flow Statement. The Cash Flow Statement determines the ending cash balance, which flows to the Balance Sheet. A circularity exists between the Debt Schedule, Income Statement, and Cash Flow Statement because interest expense reduces net income, which reduces cash, which may trigger a revolver draw, thereby increasing interest expense.

• Revenue, Assets, and Equity are positive.
• Expenses (COGS, SG&A, R&D, Interest, Taxes) are negative on the Income Statement.
• Cash outflows (Capital Expenditures, Debt Repayments, Share Repurchases) are negative on the Cash Flow Statement.
• Liabilities are positive on the Balance Sheet.

• Failing to accurately model the share issuance for the BD transaction; the model must add exactly 60,737,462 shares to the denominator for EPS calculations.
• Ignoring the $4.0 billion debt assumption from the BD transaction, which will drastically alter the interest expense profile.
• Mismodelling the mix shift; chemistry and service revenues carry significantly higher gross margins than instruments, so a faster growth rate in recurring revenue must drive gross margin expansion.
• Confusing GAAP and Non-GAAP operating margins; excluding acquisition-related amortisation flatters the adjusted margin by several hundred basis points.
• Overestimating instrument growth during pharmaceutical capital expenditure downcycles.
• Failing to account for foreign exchange impacts, which can swing reported revenue by 3% to 5% year-over-year.
• Miscalculating the deferred revenue release schedule, which is a leading indicator for service revenue growth.
• Overlooking the $733 million termination fee risk associated with the BD transaction if regulatory hurdles are not cleared.

• "Gross margin must remain between 58.5% and 60.0% based on historical stability; flag if outside this band."
• "Adjusted operating margin should be approximately 31.0%."
• "Free cash flow margin must be around 25% of revenue."
• "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
• "Pro-forma share count must increase by exactly 60.7 million shares upon BD deal close."
• "Pro-forma debt must increase by at least $4.0 billion upon BD deal close."
• "OCF to Net Income conversion should exceed 1.0x."
• "Debt/EBITDA should peak around 2.3x immediately following the BD transaction close."

• Filings: SEC EDGAR for Waters Corporation (WAT) 10-K, 10-Q, and 8-K filings.
• Presentations: Waters Investor Relations website for the 2025 Investor Day presentation and Q4 2024 earnings materials.
• Peers: Agilent Technologies (A), Thermo Fisher Scientific (TMO), and Danaher Corporation (DHR) for margin and valuation benchmarking.
• Industry Data: SDi (Strategic Directions International) for analytical instrument market share and growth data.

• Waters Corporation 2024 Annual Report on Form 10-K.
• Waters Corporation Q4 2024 Earnings Press Release.
• Waters Corporation 2025 Investor Day Presentation.
• SEC 8-K filings detailing the Becton Dickinson Biosciences & Diagnostic Solutions Reverse Morris Trust transaction.
• Financial data and consensus estimates from standard market data providers.